This year, Biofarm celebrates a century of existence on the Romanian pharmaceutical market. During the 100 years of uninterrupted activity, innovation and performance were the main values that became a solid foundation for the Biofarm business. Thus, Biofarm celebrates its centenary with remarkable financial results at the end of the first half of 2021, with significant increases compared to the same period last year.

The company's performance in the centenary year exceeds internal indicators and continues to consolidate its position in the top of the most important players in the Consumer Healthcare (CHC) category in Romania, being, after the first 6 months of 2021, on the 3rd place in terms of value, reported at the purchase price in pharmacies, while in terms of volume it rises to 2nd place, with approx. 9.8 million units sold to the final consumer.

The evolution of the CHC category in the first six months of this year was strongly influenced by the decrease registered by the cold and flu products segment, which also had an impact on one of the development areas in focus of the Biofarm portfolio. However, Biofarm is the market leader in volume in the reference categories of seven of its brands: Bixtonim, Carmol, Colebil, Triferment, Sennalax, Nervocalmin, Cavit Junior.

At the same time, in 2021, Biofarm becomes active in the market segment with the highest business potential in the CHC category - drugs for pain therapy, by launching Biofen Extra (OTC), a drug that relieves severe pain due to the synergistic combination of ibuprofen and acetaminophen.

The mix between long-lived brands and innovations in emerging categories, supported by an investment level adapted to the market context, has contributed to the consolidation of Biofarm market share in the first half of 2021, with an increase of approx. 15.5% in value, respectively 3.8% in volume, above the level of development of the CHC category.

"For Biofarm, 100 years of existence on the Romanian pharmaceutical market represents both the culmination of success and the responsibility to constantly surpass itself, to grow, to continuously innovate and to put all its resources in the service of the greater good. The year 2021 brings many major meanings and strategic objectives, as we mark a century of activity, but also new beginnings. The completion of the construction, the endowment with top equipment and the certification to GMP standards of the production unit that we opened this year are the first steps towards the future,” said Cătălin Vicol, General Manager of Biofarm.

The new production unit was inspected by the Romanian National Agency for Medicines and Medical Devices (ANMDMR) in 2021 and received the certificate of compliance with good manufacturing practice, which allows the expansion of production capacity for pharmaceutical forms to be produced in this location (capsules, tablets, film-coated tablets and caplets) once production begins in the new unit. The state-of-the-art manufacturing equipment / systems from the endowment of the new production unit allow the continuous monitoring of the processes, thus ensuring the obtaining of high-quality medicines, which meet the most rigorous requirements of the European legislation.

With a usable area of over 10,000 square meters and an annual production flow of over 30 million commercial units of tablets and capsules and over 10 million liquid products, the new Biofarm factory aligns with the company's strategic objectives: portfolio development through extensions of new product line or launches and expanding into foreign markets.

Biofarm proves that it is a visionary company that leaves its mark on doing business, the way it relates to its employees, the way it supports the well-being of patients and the way the pharmaceutical history of Romania is being written.